HIP
ALXN

Hatteras Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Hatteras Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,355
Closed -$288K – 30
2016
Q4 		$288K Sell
2,355
-800
-25% -$97.9K 1.68% 28
2016
Q3 		$387K Buy
+3,155
New +$406K 1.33% 30
2015
Q2 		– Sell
-8,659
Closed -$1.5M – 142
2015
Q1 		$1.5M Buy
+8,659
New +$1.57M 0.8% 45

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Hatteras Investment Partners's ALXN Position: Q1 2017 in Review

Hatteras Investment Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 2,355 shares — an estimated $288K sold.

Hatteras Investment Partners first reported a position in ALXN in Q1 2015 and held it in 3 quarters. The position peaked at $1.5M in Q1 2015. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Hatteras Investment Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Hatteras Investment Partners sold 2,355 Alexion Pharmaceuticals shares in Q1 2017, an estimated $288K.
  • Hatteras Investment Partners first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Hatteras Investment Partners's Alexion Pharmaceuticals position peaked at $1.5M in Q1 2015.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Hatteras Investment Partners's 13F filing for Q1 2017.